Synlogic (LTS:0A8U) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A8U Synlogic Inc LTS:0A8U
29 GF Score
Price $1.17
GF Value $0.03
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Synlogic Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0A8U
29GF Score
Synlogic Inc LTS:0A8U
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Synlogic (LTS:0A8U) Overvalued in 2026?

Based on GuruFocus' analysis, Synlogic stock appears to be overvalued. The current stock price of $1.17 is trading 3800% above its estimated GF Value™ of $0.03. GuruFocus considers Synlogic to be Significantly Overvalued.

Key valuation signals for LTS:0A8U:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $0.03 vs. price of $1.17 (3800% above fair value)
  • GF Score™: 29/100 with 1 warning sign

No single metric tells the full story. See the LTS:0A8U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synlogic Business Description

Other Exchanges SYBX:USA
Address PO Box 30, Winchester, MA, USA, 01890
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
29GF Score

Get the complete analysis for LTS:0A8U

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.17
Price
$0.03
GF Value